FIXX Annual EBITDA
-$91.52 M
+$40.46 M+30.66%
01 December 2023
Summary:
As of January 21, 2025, FIXX annual earnings before interest, taxes, depreciation & amortization is -$91.52 million, with the most recent change of +$40.46 million (+30.66%) on December 1, 2023. During the last 3 years, it has risen by +$30.77 million (+25.16%).FIXX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FIXX Quarterly EBITDA
-$9.41 M
+$14.81 M+61.14%
01 December 2023
Summary:
As of January 21, 2025, FIXX quarterly earnings before interest, taxes, depreciation & amortization is -$9.41 million, with the most recent change of +$14.81 million (+61.14%) on December 1, 2023. Over the past year, it has increased by +$14.81 million (+61.14%).FIXX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FIXX TTM EBITDA
-$91.52 M
+$24.78 M+21.31%
01 December 2023
Summary:
As of January 21, 2025, FIXX TTM earnings before interest, taxes, depreciation & amortization is -$91.52 million, with the most recent change of +$24.78 million (+21.31%) on December 1, 2023. Over the past year, it has increased by +$24.78 million (+21.31%).FIXX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FIXX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +30.7% | +61.1% | +21.3% |
| 3 y3 years | +25.2% | +61.1% | +21.3% |
| 5 y5 years | -56.1% | +61.1% | +21.3% |
FIXX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +837.7% | -1071.5% | +1906.5% |
Homology Medicines EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$91.52 M(-30.7%) | -$9.41 M(-61.1%) | -$91.52 M(-21.3%) |
| Sept 2023 | - | -$24.23 M(-20.8%) | -$116.31 M(-6.7%) |
| June 2023 | - | -$30.60 M(+12.1%) | -$124.62 M(+2.1%) |
| Mar 2023 | - | -$27.29 M(-20.2%) | -$122.00 M(-7.6%) |
| Dec 2022 | -$131.99 M(+50.7%) | -$34.20 M(+5.1%) | -$131.99 M(+2.0%) |
| Sept 2022 | - | -$32.54 M(+16.3%) | -$129.34 M(+3.2%) |
| June 2022 | - | -$27.98 M(-24.9%) | -$125.36 M(-0.4%) |
| Mar 2022 | - | -$37.27 M(+18.1%) | -$125.83 M(+43.7%) |
| Dec 2021 | -$87.60 M(-28.4%) | -$31.55 M(+10.5%) | -$87.60 M(+4.5%) |
| Sept 2021 | - | -$28.56 M(+0.4%) | -$83.79 M(+2.8%) |
| June 2021 | - | -$28.45 M(-3036.1%) | -$81.49 M(-6.1%) |
| Mar 2021 | - | $969.00 K(-103.5%) | -$86.75 M(-29.1%) |
| Dec 2020 | -$122.30 M | -$27.75 M(+5.6%) | -$122.30 M(+3.3%) |
| Sept 2020 | - | -$26.26 M(-22.1%) | -$118.39 M(-2.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2020 | - | -$33.70 M(-2.5%) | -$121.73 M(+6.4%) |
| Mar 2020 | - | -$34.59 M(+45.1%) | -$114.35 M(+10.4%) |
| Dec 2019 | -$103.63 M(+76.7%) | -$23.84 M(-19.5%) | -$103.63 M(+4.3%) |
| Sept 2019 | - | -$29.60 M(+12.4%) | -$99.39 M(+16.7%) |
| June 2019 | - | -$26.33 M(+10.4%) | -$85.16 M(+18.3%) |
| Mar 2019 | - | -$23.86 M(+21.7%) | -$72.02 M(+22.8%) |
| Dec 2018 | -$58.64 M(+102.4%) | -$19.61 M(+27.6%) | -$58.64 M(+14.8%) |
| Sept 2018 | - | -$15.37 M(+16.5%) | -$51.09 M(+21.1%) |
| June 2018 | - | -$13.19 M(+25.9%) | -$42.20 M(+21.0%) |
| Mar 2018 | - | -$10.47 M(-13.2%) | -$34.89 M(+20.4%) |
| Dec 2017 | -$28.97 M(+196.8%) | -$12.06 M(+86.3%) | -$28.97 M(+71.3%) |
| Sept 2017 | - | -$6.47 M(+10.2%) | -$16.91 M(+62.0%) |
| June 2017 | - | -$5.88 M(+28.8%) | -$10.44 M(+128.8%) |
| Mar 2017 | - | -$4.56 M | -$4.56 M |
| Dec 2016 | -$9.76 M | - | - |
FAQ
- What is Homology Medicines annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Homology Medicines?
- What is Homology Medicines annual EBITDA year-on-year change?
- What is Homology Medicines quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Homology Medicines?
- What is Homology Medicines quarterly EBITDA year-on-year change?
- What is Homology Medicines TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Homology Medicines?
- What is Homology Medicines TTM EBITDA year-on-year change?
What is Homology Medicines annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of FIXX is -$91.52 M
What is the all time high annual EBITDA for Homology Medicines?
Homology Medicines all-time high annual earnings before interest, taxes, depreciation & amortization is -$9.76 M
What is Homology Medicines annual EBITDA year-on-year change?
Over the past year, FIXX annual earnings before interest, taxes, depreciation & amortization has changed by +$40.46 M (+30.66%)
What is Homology Medicines quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of FIXX is -$9.41 M
What is the all time high quarterly EBITDA for Homology Medicines?
Homology Medicines all-time high quarterly earnings before interest, taxes, depreciation & amortization is $969.00 K
What is Homology Medicines quarterly EBITDA year-on-year change?
Over the past year, FIXX quarterly earnings before interest, taxes, depreciation & amortization has changed by +$14.81 M (+61.14%)
What is Homology Medicines TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of FIXX is -$91.52 M
What is the all time high TTM EBITDA for Homology Medicines?
Homology Medicines all-time high TTM earnings before interest, taxes, depreciation & amortization is -$4.56 M
What is Homology Medicines TTM EBITDA year-on-year change?
Over the past year, FIXX TTM earnings before interest, taxes, depreciation & amortization has changed by +$24.78 M (+21.31%)